Belpointe Asset Management LLC Purchases Shares of 2,023 Genmab A/S (NASDAQ:GMAB)

Belpointe Asset Management LLC purchased a new stake in shares of Genmab A/S (NASDAQ:GMAB – Get Rating) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 2,023 shares of the company’s stock, valued at approximately $86,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. SG Americas Securities LLC boosted its stake in shares of Genmab A/S by 4.7% during the 3rd quarter. SG Americas Securities LLC now owns 6,335 shares of the company’s stock worth $204,000 after acquiring an additional 285 shares in the last quarter. FourThought Financial LLC boosted its position in Genmab A/S by 49.8% during the 3rd quarter. FourThought Financial LLC now owns 1,227 shares of the company’s stock worth $39,000 after acquiring an additional 408 shares during the period. Simplicity Solutions LLC boosted its position in Genmab A/S by 2.3% during the 4th quarter. Simplicity Solutions LLC now owns 19,983 shares of the company’s stock worth $847,000 after acquiring an additional 458 shares during the period. Ellevest Inc. grew its stake in Genmab A/S by 7.5% during the 4th quarter. Ellevest Inc. now owns 6,568 shares of the company’s stock valued at $278,000 after acquiring an additional 461 shares in the last quarter. Finally, Bank of Montreal Can increased its holdings in shares of Genmab A/S by 1.6% in the 3rd quarter. Bank of Montreal Can now owns 36,187 shares of the company’s stock valued at $1,165,000 after purchasing an additional 585 shares during the period. 6.73% of the stock is owned by institutional investors.

Genmab A/S Price Performance

Genmab A/S stock opened at $41.64 on Friday. The company has a market capitalization of $27.47 billion, a price-to-earnings ratio of 37.51, a PEG ratio of 2.03 and a beta of 0.96. Genmab A/S has a one year low of $26.19 and a one year high of $47.50. The company’s fifty day moving average price is $39.36 and its two-hundred day moving average price is $40.53.

Genmab A/S (NASDAQ:GMAB – Get Rating) last posted its earnings results on Wednesday, February 22nd. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.35 by ($0.23). The business had revenue of $717.54 million for the quarter, compared to analyst estimates of $634.17 million. Genmab A/S had a return on equity of 19.67% and a net margin of 34.34%. As a group, sell-side analysts anticipate that Genmab A/S will post 0.99 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Morgan Stanley initiated coverage on shares of Genmab A/S in a research report on Friday, May 12th. They set an “underweight” rating on the stock. HC Wainwright boosted their price target on shares of Genmab A/S from $46.00 to $47.00 in a report on Tuesday, May 16th. SVB Leerink increased their price objective on Genmab A/S from $33.00 to $36.00 and gave the stock a “market perform” rating in a report on Monday, February 6th. Finally, Danske upgraded Genmab A/S from a “hold” rating to a “buy” rating in a research note on Thursday, February 23rd. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, Genmab A/S has an average rating of “Hold” and a consensus price target of $631.96.

Genmab A/S Profile

(Get Rating)

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia.